Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934559 | 0.89 | SLC6A2 (0.54) | SLC6A3 | |
| SCHEMBL18771277 | 0.89 | SLC6A2 (0.54) | SLC6A3 | |
| SCHEMBL16108719 | 0.89 | SLC6A2 (0.54) | SLC6A3 | |
| SCHEMBL16108720 | 0.89 | SLC6A2 (0.54) | SLC6A3 | |
| SCHEMBL14934684 | 0.86 | ADRA1D (0.49) | SLC18A2ADRA1DADRA1AADRA1B | |
| SCHEMBL16141363 | 0.86 | ADRA1D (0.49) | SLC18A2ADRA1DADRA1AADRA1B | |
| SCHEMBL14920313 | 0.83 | — | — | |
| SCHEMBL14920858 | 0.81 | — | — | |
| SCHEMBL17486636 | 0.79 | SLC18A2 (0.87) | SLC18A2HTR2ASLC6A3ADRA1DADRA1A | |
| SCHEMBL2199609 | 0.78 | SLC6A3 (0.47) | SLC18A2HTR2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | SLC18A2 2093/4885HTR2A 1527/4885SLC6A3 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.